在心力衰竭的发展过程中,慢性安洛迪平治疗
F G Spinale1, R Mukherjee, R S Krombach
1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, USA.
Circulation
|October 20, 1998
概括
在患有心力衰竭的猪中,安洛迪平治疗改善了心脏功能. 这项研究表明,在充血性心力衰竭 (CHF) 中,安洛迪平对血液动力学,神经激素和心脏收缩性有好处.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 充血性心力衰竭 (CHF) 的特征是左心室 (LV) 功能受损和血液动力学变化.
- 神经激素调节失调和区域血流减少是心血管衰竭的关键特征.
- 了解治疗干预对这些参数的影响对于管理CHF至关重要.
研究的目的:
- 为了研究慢性安洛迪平治疗对LV功能,全身血动力学和神经激素状况的影响,在CHF的猪模型中.
- 评估amlodipine对CHF患者在休息和运动期间区域血流分布的影响.
- 为了检查安洛迪平在LV肌细胞收缩功能上的体外影响.
主要方法:
- 慢性节奏诱导的充血性心力衰竭 (CHF) 在3周内在16只猪中确立.
- 猪被分为CHF和CHF与阿姆洛迪平治疗组 (每组n=8).
- 测量包括LV中风体积,全身和肺血管阻力,心肌血流量,血中诺上腺素和内分泌素水平以及LV肌细胞收缩性.
主要成果:
- 在运动期间,CHF猪表现出减少LV中风体积,增加血管阻力和减少心肌血流量.
- 阿姆洛迪平治疗使LV中风体积正常化,降低了血管阻力,并改善了心肌血流.
- 亚姆洛迪平降低了血中诺阿基尼和内啡林水平,LV肌细胞缩短速度增加.
结论:
- 慢性安洛迪平治疗在正在发展的CHF模型中显示出有利的血液动力学效应.
- 阿姆洛迪平对神经激素状况产生了积极的影响,并改善了心脏肌细胞收缩性.
- 这些发现表明,阿姆洛迪平是治疗充血性心力衰竭的有益治疗选择.
相关概念视频
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.